Abstract Introduction Chronic atrophic gastritis with accelerated progression represents a major risk factor for gastric cancer development, primarily driven by pathological processes including microbial imbalance, oxidative stress, chronic inflammation, immune dysregulation, mucin dynamics, and glycobiological disorders
GLP-1RA use was defined as having an active prescription for either semaglutide, dulaglutide, liraglutide, or tirzepatide in the electronic medical record
Taking traditional supplements means they must traverse the complex digestive process through your gastrointestinal tract, which often leads to substantial nutrient loss
Semaglutide therapy has transformed weight loss outcomes, with patients experiencing sustained appetite reduction and metabolic improvements
This is particularly important for oral semaglutide (Rybelsus), which must be taken on an empty stomach with no more than 4 ounces of water, at least 30 minutes before food, beverages, or other oral medications